Table 1 Overview of data sets used in this study.
Immunotherapy-treated cohorts | Comparison cohorts | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cohort: | PVSRIPO rGBM | Anti-PD1/PD-L1 GBM | TCGA pGBM | GLASS rGBM | Wang rGBM | |||||||
Reference: | Desjardins et al.1 | Samstein et al.8 | Zhao et al.10 | N/A | Barthel et al.11 | Wang et al.16 | ||||||
Information used for this study | Survival, TMB, RNAseq | Survival, TMB | Survival, TMB, RNAseq | Survival, TMB, RNAseq | Survival, TMB, | Survival, TMB, RNAseq | ||||||
Comparison | n | Fig. | n | Fig. | n | Fig. | n | Fig. | n | Fig. | n | Fig. |
Pre-Tx TMB vs. survival | 21 | 1a, S1 | 81 | 1c | 29 | 1d | 277 | 1e | 132 | 1f | – | – |
IDH1 wt | 19 | 1b | 76 | 1c | 21 | 1d | – | – | – | – | – | – |
Exclude MGMT meth: | 14 | S2a | – | – | – | – | – | – | – | – | – | – |
IDH1 wt; no MGMT meth: | 13 | S2b | – | – | – | – | – | – | – | – | – | – |
PTEN wt only: | 17 | S2j | – | – | – | – | – | – | – | – | – | – |
TTR vs. survival | 45 | 1b | – | – | – | – | – | – | 131a | 1g | – | – |
IDH1 wt: | 35 | S2d | – | – | – | – | – | – | – | – | – | – |
Exclude MGMT meth: | 28 | S2e | – | – | – | – | – | – | – | – | – | – |
IDH1 wt; no MGMT meth: | 22 | S2f | – | – | – | – | – | – | – | – | – | – |
TP53 mut vs. survival: | 34 | S2c | – | – | – | – | – | – | – | – | – | – |
IDH1 wt: | 31 | S2g | – | – | – | – | – | – | – | – | – | – |
Exclude MGMT meth: | 22 | S2h | – | – | – | – | – | – | – | – | – | – |
IDH1 wt; no MGMT meth: | 21 | S2i | – | – | – | – | – | – | – | – | – | – |
Steroids vs. survival (TMB cohort): | 21 | S2k | – | – | – | – | – | – | – | – | – | – |
Steroids vs. survival (TTR cohort): | 45 | S2j | – | – | – | – | – | – | – | – | – | – |
Inflammatory gene sets vs. TMB: | 14 | 2b, S4-6 | – | – | 11 | 2b, S5,6 | 193 | 2, S5,6 | – | – | 25 | 2b, S5,6 |
Immunoediting vs. TMB: | 18b | 2c | – | – | – | – | – | – | 115c | 2d | – | – |
Paired pGBM vs. rGBM | – | – | – | – | – | – | – | – | – | – | 25 | 2e/f, S8 |
